Beginning Cash: The amount of cash reported by the company on its previous statement.
Syndax Pharmaceuticals, Inc. (SNDX) had Beginning Cash of $154.30M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$172.35M |
|
$-285.42M |
|
$6.97M |
|
$165.38M |
|
$445.44M |
|
$-273.08M |
|
$-12.34M |
|
$-285.42M |
|
$-285.42M |
|
$-285.42M |
|
$-285.42M |
|
$-285.42M |
|
$-285.42M |
|
$-273.08M |
|
$-283.60M |
|
86.63M |
|
86.63M |
|
$-3.29 |
|
$-3.29 |
|
| Balance Sheet Financials | |
$528.08M |
|
$0.18M |
|
$1.62M |
|
$529.71M |
|
$120.12M |
|
$343.91M |
|
$344.96M |
|
$465.08M |
|
$64.63M |
|
$64.63M |
|
$64.63M |
|
87.41M |
|
| Cash Flow Statement Financials | |
$-322.98M |
|
$290.04M |
|
$13.68M |
|
|
Beginning Cash |
$154.30M |
$135.03M |
|
$-19.27M |
|
$47.50M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.40 |
|
-- |
|
-- |
|
0.84 |
|
5.32 |
|
95.96% |
|
-158.45% |
|
-158.45% |
|
-164.55% |
|
-165.60% |
|
-165.60% |
|
$-323.17M |
|
-- |
|
-- |
|
-- |
|
0.33 |
|
0.21 |
|
2.53 |
|
144.31 |
|
-441.62% |
|
-441.62% |
|
-53.88% |
|
-69.86% |
|
$0.74 |
|
$-3.73 |
|
$-3.73 |
|